These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

868 related articles for article (PubMed ID: 27650977)

  • 1. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
    Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
    Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
    Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
    Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
    BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
    Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
    Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
    Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
    Wysham C; Bonadonna RC; Aroda VR; Puig Domingo M; Kapitza C; Stager W; Yu C; Niemoeller E; Souhami E; Bergenstal RM;
    Diabetes Obes Metab; 2017 Oct; 19(10):1408-1415. PubMed ID: 28386990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
    Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
    Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
    Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
    Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
    Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
    Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
    Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
    Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
    Frias J; Puig Domingo M; Meneghini L; Napoli R; Liu M; Soltes Rak E; Aroda VR
    Diabetes Obes Metab; 2018 Sep; 20(9):2314-2318. PubMed ID: 29785837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
    Davies MJ; Rosenstock J; Ali A; Russell-Jones D; Souhami E; Palmer K; Ji C; Niemoeller E; Skolnik N
    Diabetes Obes Metab; 2022 Jan; 24(1):34-41. PubMed ID: 34617398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
    Skolnik N; Dupree RS; Johnson EL
    Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mexican population sub-analysis of the lixilan clinical program with the fixed ratio combination of insulin glargine and lixisenatide (iGlarLixi).
    González-Gálvez G; Díaz-Toscano ML; Llamas-Moreno JF; Fernández-Rodarte K; Sañudo-Maury ME
    J Diabetes Complications; 2020 Aug; 34(8):107389. PubMed ID: 32561160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
    Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
    Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
    Blonde L; Rosenstock J; Del Prato S; Henry R; Shehadeh N; Frias J; Niemoeller E; Souhami E; Ji C; Aroda VR
    Diabetes Care; 2019 Nov; 42(11):2108-2116. PubMed ID: 31530665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.